FASN

Overview

FASN encodes fatty acid synthase, a key enzyme in de novo lipogenesis. In cancer, FASN is frequently upregulated and supports rapid membrane biosynthesis and energy storage in tumor cells. In clear-cell renal cell carcinoma (ccRCC), FASN is highlighted as part of the metabolic reprogramming landscape identified by comprehensive genomic and epigenomic profiling.

Alterations observed in the corpus

  • Highlighted as a downstream pathway and SCNA feature in focal-deletion analyses in clear-cell renal cell carcinoma (ccRCC), as part of a broader metabolic alteration pattern (Warburg-like shift) in aggressive tumors PMID:23792563

Cancer types (linked)

  • CCRCC — identified as part of the metabolic reprogramming landscape; aggressive ccRCC tumors show Warburg-like shift with altered lipid and glucose metabolism PMID:23792563

Co-occurrence and mutual exclusivity

Therapeutic relevance

  • Metabolic biomarkers including AMPK, ACC, and pentose phosphate pathway genes are proposed as candidate therapeutic-vulnerability indicators in aggressive ccRCC PMID:23792563

Open questions

  • Specific frequency of FASN copy-number gain or expression alteration in the ccRCC TCGA cohort is not detailed individually PMID:23792563

Sources

This page was processed by crosslinker on 2026-05-09.